End-Stage Kidney Disease following Surgical Management of Kidney Cancer

Ellis, Robert J.; Edey, D.; Vecchio, Sharon J. Del; McStea, Megan; Campbell, Scott; Hawley, Carmel; Johnson, David W.; Morais, Christudas; Jordan, Susan J.; Francis, Ross; Wood, Simon; Gobé, Glenda C.; Queensland, Cancer Alliance

doi:10.2215/cjn.06560518

Cited by 14 publications

(17 citation statements)

References 34 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 The finding that patients managed in private, compared with public, hospitals are at greater risk of incident CKD has not been previously reported in Australia; however, we recently reported that there were no differences in the rate of ESKD in patients managed surgically for kidney cancer in public compared with private centres in Queensland between January 2009 and December 2014. 9 This may indicate that the association observed in the current study was too small to lead to an appreciable difference in rates of ESKD, or that there was insufficient time for this difference in CKD incidence to manifest as a difference in the development ESKD. It is not clear why patients managed in private hospitals had a higher rate of CKD, but this warrants further exploration.…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 67%

“…The incidence rate of ESKD after radical nephrectomy for kidney cancer is approximately 5.2 per 1,000 person-years. 9 Additionally, patients with a previously normal kidney function who develop de novo CKD after radical nephrectomy have a higher mortality rate than patients who do not develop CKD after nephrectomy. 10,11 Identifying patients who are at risk of CKD following radical nephrectomy could improve patient care, as appropriate risk stratification prior to surgery could be conducted to help guide management and follow-up.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Incident Chronic Kidney Disease After Radical Nephrectomy for Renal Cell Carcinoma

Ellis

White

Coory

et al. 2019

Clinical Genitourinary Cancer

Self Cite

View full text Add to dashboard Cite

MicroAbstract Chronic kidney disease (CKD) following radical nephrectomy is common, and associated with an increased risk of morbidity and mortality. This study utilised population-based samples from the Australian states of Queensland and Victoria to identify factors which were associated with a higher likelihood of developing CKD. Apart from recognised CKD risk factors, rural place of residence, and being managed in private compared with public hospitals was associated with higher odds of CKD.

show abstract

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 67%

Section: Introductionmentioning

confidence: 99%

Incident Chronic Kidney Disease After Radical Nephrectomy for Renal Cell Carcinoma

Ellis

White

Coory

et al. 2019

Clinical Genitourinary Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…16 In addition, preoperative kidney disease is associated with a 15fold increased risk of ESKD after surgical resection. 17 Survival data in CKD and ESKD emphasize why management of kidney disease becomes more important than management of kidney cancer. According to the 2014 US Renal Data System, the average 60-, 70-, or 80-year-old with ESKD on dialysis has a life expectancy of 5.6, 3.9, or 2.7 years, respectively, which is substantially lower than the life expectancy of any RCC patient with stage I, II, or III disease.…”

Section: Epidemiology and Risk Factors For Rcc And Ckdmentioning

confidence: 99%

The Importance of Nephropathology in Kidney Cancer

Henriksen

Chang

2020

Seminars in Nephrology

View full text Add to dashboard Cite

“…Risk factors most strongly associated with the development of ESKD are older age, male sex, diabetes, and preoperative CKD. 29 , 30 …”

Section: Key Findingsmentioning

confidence: 99%

Perspectives From an Onconephrology Interest Group: Conference Report

Kitchlu

Chan

Leung

et al. 2020

Can J Kidney Health Dis

View full text Add to dashboard Cite

Introduction and objective: Onconephrology is a new and evolving field that deals with kidney complications in patients with cancer as well as the management of cancer in patients with preexisting kidney disease. With increasing numbers of patients with cancer with kidney-related complications, the field has garnered increased attention. Thus, an annual Greater Toronto Area Onconephrology Interest Group symposium was held in May 2019. The objective of the meeting was to demonstrate the junctures between oncology and nephrology by highlighting recent data regarding (1) kidney impairment in solid organ malignancies, (2) management and treatment of kidney cancer, (3) kidney impairment in hematologic malignancies, (4) malignancy and kidney transplantation, and (5) hyponatremia in patients with cancer. Methods and sources of information: Through a structured presentation, the group explored key topics discussed at a Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Onconephrology. Expert opinions, clinical trial findings, and publication summaries were used to illustrate patient and treatment-related considerations in onconephrology. Key findings: Kidney complications in patients with cancer are a central theme in onconephrology. An estimated 12% to 25% of patients with solid organ malignancies have chronic kidney disease (CKD), although in certain cancers, the prevalence of CKD is higher. Kidney impairment is also a common complication of some hematologic malignancies. The incidence of renal failure in patients with multiple myeloma is estimated at 18% to 56% and light chain cast nephropathy is seen in approximately 30% of these patients. In addition, there appears to be a bidirectional relationship between kidney cancer and CKD, with some data sets suggesting the risk increases as kidney function declines. Cancer is also of concern in patients with preexisting kidney disease. Kidney transplant recipients have a greater risk of cancer and a higher risk of cancer-related mortality. Kidney complications have also been associated with novel cancer therapies, such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy. An estimated 2% to 4% of patients initiating an immune checkpoint inhibitor may develop nephrotoxicity, whereas up to 40% of patients on CAR T-cell therapy experience cytokine release syndrome (CRS). Tumor lysis syndrome and electrolyte abnormalities, such as hyponatremia, have also been reported with CAR T-cell therapy. While the incidence and prevalence of hyponatremia vary depending on the cancer type and serum sodium cutoff point, hyponatremia may be seen in up to 46% of patients hospitalized in cancer centers. Conclusions: Onconephrology is a developing field and the themes arising from this meeting indicate a need for greater collaboration between oncologists and nephrologists. Educational symposia and onconephrology fellowship programs may allow for improved cancer care for patients with kidney disease.

show abstract

End-Stage Kidney Disease following Surgical Management of Kidney Cancer

Cited by 14 publications

References 34 publications

Incident Chronic Kidney Disease After Radical Nephrectomy for Renal Cell Carcinoma

Incident Chronic Kidney Disease After Radical Nephrectomy for Renal Cell Carcinoma

The Importance of Nephropathology in Kidney Cancer

Perspectives From an Onconephrology Interest Group: Conference Report

Contact Info

Product

Resources

About